Chronic treatment with the CB1R antagonist rimonabant (RIM) leads to weight loss and increased insulin sensitivity in multiple models of obesity, including rodents [11,12], canines [13,14], and humans [15]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.